Results 101 to 110 of about 17,404,319 (246)

Multi‐Target Pharmacological Mechanisms of Salvia miltiorrhiza Bunge in Metabolic Syndrome and Cardiovascular Diseases: A Comprehensive Review Based on the Theory of “Same Treatment for Different Diseases”

Phytotherapy Research, EarlyView.
Salvia miltiorrhiza Bunge in metabolic syndrome and cardiovascular diseases: multi‐target actions on shared signaling pathways. ABSTRACT Metabolic syndrome (MetS) represents a clinical disorder characterized by the clustering of conditions including obesity, elevated blood sugar levels, and high lipid levels, which are intricately linked to the onset ...
Zhiyi Jia, Kaiyi Wu, Jiaying Qi, Nana Huang, Yusheng Liu, Xiumei Gao, Rong Sun   +6 more
wiley   +1 more source

Natural Products Exhibit Therapeutic Potential in Treating Rheumatoid Arthritis by Targeting the PI3K/Akt Signaling Pathway

Phytotherapy Research, EarlyView.
This review summarizes how natural products, mainly including flavonoids, terpenoids, alkaloids, and polyphenols alleviate RA via PI3K/Akt pathway, regulating inflammation, proliferation, apoptosis, angiogenesis, and osteoclast differentiation. The figure was created by Figdraw (https://www.figdraw.com/#/).
Haishuo Ren, Yige Wang, Wenjing Ma, Omachi Daniel Ogaji, Shujing Chen, Kunze Du, Xuemi Zhang, Bo Xu, Shanxing Zhai, Shiming Fang, Yanxu Chang   +10 more
wiley   +1 more source

Oral manifestations in glycogen storage disease type 1b

, 1995
Glycogen storage disease type 1b is a rare metabolic disorder which affects the transport system of glucose‐6‐phosphatase metabolism. As a result, hepatomegaly, failure to thrive, renal dysfunction and recurrent infections occur in affected patients.
Drogari, E., Harokopos, E., Laskaris, G., Messaritakis, J., Salapata, Y.   +4 more
core   +1 more source

History of glycogen storage disease type Ⅱ

, 2018
Glycogen storage disease type Ⅱ (GSD Ⅱ), which is also called Pompe disease, is an autosomal recessive hereditary metabolic disease resulting from mutations of acid α-glucosidase (GAA).
Cheng ZHANG, Liang WANG
core   +1 more source

Rotenone Induces Morphological Damage and Reduction in Catecholamine Levels in the Central Nervous System of the Ascidian Styela plicata

Environmental Toxicology, EarlyView.
ABSTRACT Ascidians are invertebrates that occupy a key phylogenetic position as a sister group of the vertebrates. The organization of their central nervous system (CNS), with cortex and medulla, indicates a plesiomorphic character of the gray and white matter of vertebrates, making this group of animals useful for studies of neurodegenerative events ...
Andressa de Abreu Mello, Carlos Augusto Borges de Andrade Gomes, Rafaela Rocha dos Santos, Cintia Monteiro de Barros, Silvana Allodi   +4 more
wiley   +1 more source

Incidence and Risk Factors of Late‐Onset Hypoglycemia in Extremely Low Gestational Age or Extremely Low Birth Weight Infants

Acta Paediatrica, EarlyView.
ABSTRACT Aim To determine incidence and risk factors associated with late‐onset hypoglycemia in extremely preterm or extremely low birth weight infants. Methods Retrospective single‐center cohort study including infants with a gestational age < 28 weeks or birth weight < 1000 g.
Lara Canova, Roland P. Neumann, Sven M. Schulzke   +2 more
wiley   +1 more source

Late-onset Pompe’s disease in pediatrics: results from an Italian national survey on 38 patients and proposal of a targeted diagnostic algorithm

Orphanet Journal of Rare Diseases
Background Late-onset Pompe’s disease (LOPD) is a progressive treatable metabolic myopathy due to partial acid α-glucosidase (GAA) deficiency, with potential onset during the pediatric age.
Marco Spada, Serena Gasperini, Massimiliano Filosto, Guja Astrea, Beatrice Bracci, Claudio Bruno, Alberto Burlina, Anna Cavallini, Daniela Concolino, Viola Crescitelli, Adele D’Amico, Federica Deodato, Carlo Dionisi-Vici, Maria Alice Donati, Simona Fecarotta, Rita Fischetto, Agata Fiumara, Francesca Furlan, Vincenza Gragnaniello, Damiano Mala, Monica Marica, Francesca Menni, Veronica Pagliardini, Claudia Panicucci, Giancarlo Parenti, Andrea Pession, Federica Ricci, Valentina Rovelli, Michele Sacchini, Filippo Maria Santorelli, Lucia Santoro, Maurizio Scarpa, Roberta Taurisano, Albina Tummolo, Francesco Porta   +34 more
doaj   +1 more source

LEUKOCYTE DEBRANCHING ENZYME IN GLYCOGEN STORAGE DISEASE

, 1962
In recent years the classification of glycogen storage disease has been based on the demonstration of a specific enzyme defect for each type (1-4). Type I, glycogenosis or von Gierke's disease, results from the lack of glucose 6-phosphatase (1 ...
E. Williams, Esther M. Kendig, James B
core  

Diabetes mellitus in a patient with glycogen storage disease type Ia: a case report

, 2017
Background Glycogen storage disease type Ia is a genetic disorder that is associated with persistent fasting hypoglycemia and the inability to produce endogenous glucose. The development of diabetes with glycogen storage disease is exceedingly rare.
Anupam Ohri, Aviva Cohn
core   +1 more source

A novel myopathy with autophagic vacuoles associated with biallelic variants in CLN8

Brain Pathology, EarlyView.
We describe a novel adult‐onset myopathy with autophagic vacuoles and characteristic features of ceroid lipofuscinosis associated with biallelic CLN8 variants, seizures, and muscle weakness. Autophagosomal/lysosomal deposition of curvilinear, autofluorescent material containing the mitochondrial adenosine triphosphate (ATP) synthase membrane subunit c ...
Ulrika Lindgren, Carola Hedberg‐Oldfors, Kittichate Visuttijai, Sara Nordström, Hans Goebel, Anders Oldfors   +5 more
wiley   +1 more source